Анализ акций SMSPHARMA.NS
SM
Нет оценки
Количественный анализ Eyestock не покрывает акции SMS Pharmaceuticals Ltd.
Капитализация млрд. $
0.047
Дивидендная доходность
0.25 %
Оборот
84.652 млрд
Сайт компании
https://smspharma.com/SMS Pharmaceuticals Ltd. is a holding company, which engages in the research, development and marketing of active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana and currently employs 1,095 full-time employees. The company went IPO on 2007-02-25. The firm is engaged in the business of manufacturing of active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic and others. The firm products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel and lamotrigine. The firm has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.